SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Fluidigm Corporation (NASDAQ:FLDM) today announced that MLL Munich Leukemia Laboratory (www.mll.com) has used the company’s Access Array™ technology to help it uncover mutations in over 80 percent of chronic myelomonocytic leukemia (CMML) patients, providing new insights into the molecular heterogeneity of the disease. MLL researchers applied the unique properties of the Fluidigm Access Array System to prepare the samples and barcode the amplicons for next-generation deep-sequencing using 454 sequencing technology.
